Funding Opportunity RFA-HL-21-012 from the NIH Guide for Grants and Contracts. The purpose of this limited competition Funding Opportunity Announcement (FOA) is to support the continuation and expansion of the existing NHLBI Pulmonary Trials Cooperative (PTC) clinical trials network. This FOA requests applications for a cooperative agreement research grant (U24) to serve as the Network Management Core (NEMO) for the PTC. The PTC will include multiple Protocol Leadership Groups (PLGs) and a single Network Management Core (NEMO) and will conduct multiple simultaneous phase II clinical trials that will test innovative disease modifying therapies (DMT) for adult chronic lung diseases. NEMO will have primary responsibility for organizing and operating this multi-center cooperative.

Funding Opportunity RFA-HL-21-013 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support multiple Protocol Leadership Groups (PLGs) that will conduct phase II trials within the NHLBI Pulmonary Trials Cooperative (PTC) clinical trials network. The PTC will include multiple Protocol Leadership Groups (PLGs) and a single Network Management Core (NEMO) and will conduct multiple simultaneous phase II clinical trials that test innovative disease modifying therapies (DMT) for chronic lung diseases.

Notice NOT-EY-20-007 from the NIH Guide for Grants and Contracts

Notice NOT-EY-20-008 from the NIH Guide for Grants and Contracts

Notice NOT-NS-20-065 from the NIH Guide for Grants and Contracts

Notice NOT-HL-20-783 from the NIH Guide for Grants and Contracts

Notice NOT-NS-20-051 from the NIH Guide for Grants and Contracts

Notice NOT-NS-20-057 from the NIH Guide for Grants and Contracts

Notice NOT-NS-20-058 from the NIH Guide for Grants and Contracts

Notice NOT-CA-20-058 from the NIH Guide for Grants and Contracts

Notice NOT-CA-20-049 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-20-179 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications that seek to improve the availability, quality, and utility of data and measures that capture multimorbidity or multiple chronic conditions (MCCs) and the methods for analyzing multimorbidity data. Research supported by this initiative should be designed to discover, develop, and/or evaluate MCC measures/tools that reflect the longitudinality and life course diversity of multimorbidity. This includes but is not limited to measures/tools to support basic mechanistic discovery of shared MCC pathways using animal models of MCCs, and identification and initial biological, analytical, and clinical evaluation of MCC shared signatures. Also sought are patient-focused studies that capture patient reports and related constructs such as functional limitations and quality of life; analytic approaches best suited for use with multimorbidity data and matched to target populations; and approaches that fully harness the wealth of multimorbidity data available in EHR systems. Studies may make use of existing data and data linkages to explore new research questions related to co-occurring MCCs. Prospective applicants whose research interests relate to studies that identify shared mechanisms or development of innovative interventions to address MCCs should see PAR-XX-XXX.

Funding Opportunity PAR-20-180 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications that seek to support the identification of shared mechanisms and development of innovative interventions to address multimorbidity (or multiple chronic conditions (MCCs)) and its consequences. Intervention research supported by this initiative should be designed to study: (1) mechanisms or pathways that prevent MCCs, including the identification of early biomarkers, behavioral pathways, and individual and contextual risk factors and interactions that contribute to the development of common MCCs; (2) targeted therapies and management, including self-management, of MCCs to delay progression and prevent onset of new diseases; and (3) innovative health care partnership models for managing or treating MCCs. Studies may include shared mechanisms, and assessments of interactions between risk factors and interventions that address MCCs at different periods of the lifespan in diverse populations. Use of innovative technologies to assess and intervene on risk factors and pathways are encouraged. Studies may also include those that make use of existing data and/or data linkages to explore new research questions that may be helpful in understanding the impact of mechanisms in isolation or in combination. Of particular interest are interventions that target prevention and treatment of multiple chronic health conditions, including study designs that address therapeutic targets for preventing co-occurring multiple chronic conditions. Prospective applicants whose research interests relate to developing improved measures and methods for understanding multimorbidity, including but not limited to measures/tools to support basic mechanistic discovery of shared MCC pathways and identification and initial evaluation of MCC shared signatures, should see PAR-XX-XXX.

In Bioinformatics, Computational Biology, or a related field; In Bioinformatics, Computational Biology, or a related field.
From Marshall University - Wed, 29 Apr 2020 18:58:39 GMT - View all Huntington, WV jobs

Funding Opportunity RFA-ES-20-010 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement is to promote collaborative research among US and Indian scientists in the field of environmental health research with a focus on air pollution.

Funding Opportunity PA-20-072 from the NIH Guide for Grants and Contracts. The Agency for Healthcare Research and Quality (AHRQ) hereby notifies grantees holding active AHRQ awards that were funded under the PCOR FOAs, (see referenced FOAs under: Part 1. Overview Information, Activity Code), that funds are available for competitive revisions to meet immediate needs to help address timely health system and healthcare professional response to the COVID-19 public health crisis. This FOA does not include grants that were awarded using AHRQ Health Service Research (HSR) dollars (please see FOA number PA-20-070, which is directed toward those grants). It is expected that competitive revision supplement requests will capitalize on the expertise of grant personnel and the institutional environment to expand the specific aims of the on-going research to develop high-impact new knowledge concerning COVID-19. The proposed projects must support dissemination of comparative clinical effectiveness research findings or the training of researchers in the methods used to conduct such research. Funding will be available in Fiscal Year 2020.

Funding Opportunity PA-20-070 from the NIH Guide for Grants and Contracts. The Agency for Healthcare Research and Quality (AHRQ) hereby notifies grantees holding active AHRQ awards, (except R13s, T32s, F32s), that funds are available for competitive revisions to meet immediate needs to help address timely health system and healthcare professional response to the COVID-19 public health crisis. This FOA does not include grants that were previously funded under FOAs supported by Patient Centered Outcome Research Trust Fund (PCOR TF) dollars (Please see FOA number PA-20-072, which is directed towards those grants).

Notice NOT-HL-20-755 from the NIH Guide for Grants and Contracts

Notice NOT-TR-20-025 from the NIH Guide for Grants and Contracts

F. Hoffmann-La Roche AG: Who we areAt Roche, over 90,000 people across 150 countries are pushing back the frontiers of healthcare. Working together, we’ve become one of the w Switzerland (CH)